US FDA Sends Amgen/UCB Evenity Back With BRIDGE Request

The US FDA has surprised no-one with a Complete Response Letter for Amgen and UCB's novel osteoporosis treatment Evenity but, with luck, analysts say the product might still reach the market in 2018-19 and garner sales over £500m.

Boots — BRIDGE Over Evenity's Troubled Waters • Source: Shutterstock

Amgen Inc./UCB SA's investigational therapy for osteoporosis Evenity (romosozumab) could still bring in sales of more than half a billion dollars despite delays to market and concerns over its adverse event profile, say analysts as the product received a Complete Response Letter from the US FDA.

Hopes for a swift approval for the first-in-class sclerostin inhibitor died when a cardiovascular safety signal overshadowed positive efficacy data...